

5/8/02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3
PATENT APPLICATION
Docket No.: 302018.3003-100
Prior No.: 98,301

1614

TECH CENTER 1600/2900

MAY 21 2002

RECEIVED

Applicants: Daniel R. Salomon, Donald V. Cramer
Application No.: 10/006,562 Group Art Unit: 1614
Filed: December 5, 2001 Examiner: Not Assigned
Title: Composition and Method for Treating Chronic Allograft Rejection

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231		
on	5/13/02	Signature
Date	Denise Shaeffer	
Typed or printed name of person signing certificate		

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This Information Disclosure Statement is submitted:

under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)

under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).

under 37 CFR 1.97(c) together with either:
 a Statement under 37 CFR 1.97(e), as checked below, or
 a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

under 37 CFR 1.97(d) together with:
 a Statement under 37 CFR 1.97(e), as checked below, and
 a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Enclosed herewith is form PTO-1449:

- Copies of the cited references are enclosed.
- Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- Listed references were cited in the enclosed International Search Report in a counterpart foreign application.

Concise Explanation Requirement (non-English references):

- The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
 - the explanation provided on the attached sheet.
 - the explanation provided in the Specification.
 - submission of the enclosed International Search Report.
 - the enclosed English language abstract.

Applicant requests that the following pending applications be considered:

Examiner's
Initials

U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], Publication No. [], Publication Date [],
by [inventor(s)], filed [], Docket No.: []

Examiner

Date

A copy of each above-cited application, including the current claims, is enclosed.

A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.


Please charge Deposit Account 50-1935 in the amount of \$[]. A copy of this Statement is enclosed.

Please charge any deficiency in fees and credit any overpayment to Deposit Account 50-1935.

Respectfully submitted,

BOWDITCH & DEWEY, LLP

By


Roger P. Zimmerman
Registration No.: 38,670
Telephone: (508) 879-5700
Facsimile: (508) 929-3073

Framingham, Massachusetts 01701-9320

Dated: *May 13, 2002*



PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 13, 2002 (Use several sheets if necessary)				ATTORNEY DOCKET NO. 302018.3003-100 (98-301)	APPLICATION NO. 10/006,562		
APPLICANT Salomon, D.R. et al.				FILING DATE December 5, 2001	GROUP 1614		
TECH CENTER 1600/2900 RECEIVED MAY 21 2002							
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
✓	AR	Cramer, D.V. et al., "2-Chlorodeoxyadenosine in Combination With Cyclosporine Inhibits the Development of Transplant Arteriosclerosis in Rat Cardiac Allografts," <i>Transplantation Proceedings</i> , 29:616 (1997)					
	AS	Demetris, A.J. et al., "Analysis of Chronic Rejection and Obliterative Arteriopathy," <i>American Journal of Pathology</i> , Vol. 150, No 2: 563-578 (1997)					
	AT	Häyry, P., "Pathophysiology of Chronic Rejection," <i>Transplantation Proceedings</i> , Vol 28, No 6, Suppl 1, 7-10 (1996)					
	AU	Häyry, P. et al., "Towards Understanding the Pathophysiology of Chronic Rejection," <i>Clin Investig</i> 70:780-90 (1992)					
✓	AV	Nawrocki, G. et al., "Prolongation of Cardiac Allograft Survival in Rats Following Combination Treatment With 2-Chloro-2'-Deoxyadenosine and Cyclosporine," <i>Transplantation Proceedings</i> , Vol. 28, No. 6 pp.3538-39 (1996)					
✓	AW	Nowaczyk, M. et al., "2-Chlorodeoxyadenosine: Lack of Synergism with Cyclosporine A and Tacrolimus (FK506)," <i>Arch Immunol Ther Exp. Warsz</i> 43(5-6):329-32 (1995)					
	AX	Orosz, C. G. et al., "Chronic Remodeling Pathology in Grafts," <i>Current Opinion in Immunology</i> 9:676-680 (1997)					
	AY	Rao, V. K., "Posttransplant Medical Complications," <i>Surgical Clinics of North America</i> Vol. 78 No. 1: 113-132 (1998)					
✓	AZ	Schmid, T. et al., " 2-Chlorodeoxyadenosine in Combination with Cyclosporine Prevents Rejection After Allogenic Small Bowel Transplantation" <i>Transplantation Proceedings</i> , Vol. 26 No. 3: 1614 (1994)					
✓	AA2	Schmid, T. et al., " 2-Chlorodeoxyadenosine in Combination with Low-Dose Cyclosporine Prevents Rejection After Allogenic Heart and Liver Transplantation in the Rat," <i>Eur Surg Res</i> 30:61-68 (1998)					
	AB2	Schmid, T. et al., "Histologic Pattern of Small Bowel Allograft Rejection in the Rat," <i>Gastroenterology</i> Vol. 96 No. 6, pp.1529-32 (1989)					
	AC2	Wu, G.D. et al., "FK 506 Inhibits the Development of Transplant Arteriosclerosis," <i>Transplantation Proceedings</i> Vol. 23, No. 6 pp. 3272-3274 (1991)					